TrialReproductive biology and endocrinology : RB&E2015

Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulation.

Andreas Lammerich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.